Heart Disease News and Research

Latest Heart Disease News and Research

Capillary pCO2 helps determine IPAH diagnosis

Capillary pCO2 can be used to distinguish idiopathic pulmonary arterial hypertension from pulmonary hypertension due to heart failure with preserved ejection fraction, research indicates.

14 Apr 2015

New study describes way to regenerate lung tissue after injury

A new collaborative study describes a way that lung tissue can regenerate after injury. The team found that lung tissue has more dexterity in repairing tissue than once thought.

13 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

Latest findings regarding nitric oxide offer new avenues to save lives

Professor Jonathan Stamler's latest findings regarding nitric oxide have the potential to reshape fundamentally the way we think about the respiratory system - and offer new avenues to save lives. It may be time to rewrite the textbooks.

13 Apr 2015

Toronto General Hospital unveils novel technology-based platform to improve patient care

The Toronto General Hospital today becomes the first healthcare institution in the world to unveil a novel technology-based platform aimed at shortening the time required to translate medical research into clinical practice. This will enable faster diagnoses and more rapid treatment for patients with heart disease and other conditions that are detected using advanced medical imaging devices.

13 Apr 2015

Researchers cultivate fully functional cardiac tissues from cobweb protein

Genetically engineered fibers of the protein spidroin, which is the construction material for spider webs, has proven to be a perfect substrate for cultivating heart tissue cells, MIPT researchers found. They discuss their findings in an article that has recently come out in the journal PLOS ONE.

13 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Duke-NUS study shows association between eating out and high blood pressure

A recent study on university-going young adults, by researchers from the Duke-NUS Graduate Medical School Singapore, is the first ever to show an association between meals eaten away from home and high blood pressure.

12 Apr 2015

Philips launches connected health technology solutions at HIMSS15

Royal Philips today announced its participation in the 2015 HIMSS Annual Conference & Exhibition (HIMSS15), taking place April 12-16 in Chicago, Ill.

10 Apr 2015

Fraunhofer researchers develop cell-free substrate made of advanced fibers

Regenerative medicine uses cells harvested from the patient's own body to heal damaged tissue. Fraunhofer researchers have developed a cell-free substrate containing proteins to which autologous cells bind and grow only after implantation.

10 Apr 2015

Stem cell disease model reveals how tumor suppressor may drive bone cancer

Using induced pluripotent stem cells (iPSCs), a team led by Mount Sinai researchers has gained new insight into genetic changes that may turn a well known anti-cancer signaling gene into a driver of risk for bone cancers, where the survival rate has not improved in 40 years despite treatment advances.

10 Apr 2015

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.

10 Apr 2015

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center.

10 Apr 2015

Changing the size and number of pores in processed foods can reduce salt intake

Two University of Illinois food scientists have learned that understanding and manipulating porosity during food manufacturing can affect a food's health benefits.

10 Apr 2015

Scientists identify chemical compounds that block cancer-causing oncoprotein

A team of scientists at the University of Kansas has pinpointed six chemical compounds that thwart HuR, an "oncoprotein" that binds to RNA and promotes tumor growth.

10 Apr 2015

Amniotic stem cells promote growth of functional blood vessels in healing hydrogels

Rice University and Texas Children's Hospital scientists are using stem cells from amniotic fluid to promote the growth of robust, functional blood vessels in healing hydrogels.

10 Apr 2015

Gratitude in heart attack patients improves cardiac health

Recognizing and giving thanks for the positive aspects of life can result in improved mental, and ultimately physical, health in patients with asymptomatic heart failure, according to research published by the American Psychological Association.

10 Apr 2015

Cardiome Pharma receives reimbursement status for BRINAVESS in Belgium

Cardiome Pharma Corp. today announced the approval of BRINAVESS for reimbursement by Belgium's national compulsory health care and benefits insurance authority, The National Institute for Health and Disability Insurance (Institut National d'Assurance Maladie Invalidité or INAMI). As a result of this decision, BRINAVESS is expected to be listed for reimbursement in Belgium as of June 1, 2015.

9 Apr 2015

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%.

9 Apr 2015

Shorter individuals at greater risk of heart disease

In a study of more than 200,000 people with or without heart disease, researchers from the University of Leicester found that for every 2.5 inch decrease in a person’s height, the risk of coronary heart disease increased by 13.5%...

9 Apr 2015